Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.42 |
| ▸ | LPL | P06858 | 13/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32684357 | 0.85 | LPL (0.41) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL12279506 | 0.84 | LIPG (0.57) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL31035172 | 0.82 | LIPG (0.44) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL16419567 | 0.80 | LIPG (0.47) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL38651383 | 0.79 | LPL (0.42) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL2695426 | 0.79 | LIPG (0.42) | LIPGLPLROCK1AAK1F11 | |
| SCHEMBL1555488 | 0.78 | HTR2A (0.44) | LIPGLPL | |
| SCHEMBL30470776 | 0.77 | LIPG (0.65) | TAAR1LIPGLPL | |
| SCHEMBL24364496 | 0.77 | LIPG (0.65) | TAAR1LIPGLPL | |
| SCHEMBL15788300 | 0.75 | LPL (0.67) | TAAR1LIPGLPLF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TAAR1 555/4885LIPG 2618/4885LPL 2221/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TAAR1 555/4885LIPG 2618/4885LPL 2221/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TAAR1 295/4885LIPG 1319/4885LPL 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.